WLWei Liu

Wei Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Liu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PKM2-Mediated Glycolytic Reprogramming in Thyroid Cancer: Mechanistic Insights and Therapeutic Potential

    by Shenshen Li, Wei Liu, Jiaojiao Zheng, Lingyu Ren, Changhao Zhou, Qiao Wu, Zhilong Ai

    Thyroid cancer (TC) is an endocrine malignant tumor with the fastest-growing incidence worldwide. It has complex pathological types and significant heterogeneity, with great differences in clinical prognosis among different subtypes. Among them, aggressive subtypes, such as radioiodine-refractory (RAI-R) TC and anaplastic thyroid cancer (ATC), have become a major challenge in current clinical diagnosis and treatment, due to limited treatment options and high risks of recurrence and metastasis. Tumor metabolic reprogramming is one of the characteristics of cancer, among which the Warburg effect plays a driving role. As a rate-limiting enzyme in the glycolytic pathway, pyruvate kinase M2 (PKM2), with its unique functional plasticity, has become a linchpin of glycolytic metabolism and malignant phenotypes of tumor cells. This article will systematically review the functional regulatory mechanisms of PKM2, its specific role in TC, and explore the targeted therapeutic strategies and research prospects of TC with PKM2, providing a new theoretical basis and potential plans for the clinical diagnosis and treatment.

  • Open Access

    The Role of Mitochondrial Genome Stability and Metabolic Plasticity in Thyroid Cancer

    by Lingyu Ren, Wei Liu, Jiaojiao Zheng, Qiao Wu, Zhilong Ai

    Mitochondria play a central role in energy metabolism, redox homeostasis, and signal transduction in the thyroid cells. Increasing evidence indicates that mitochondrial DNA (mtDNA) mutations, copy number variations, and haplogroup-specific polymorphisms are closely associated with metabolic reprogramming and malignant progression of thyroid cancer. This review summarizes recent advances in the understanding of the impact of mitochondrial genome instability and metabolic plasticity on thyroid tumorigenesis. We discuss how mtDNA alterations disrupt oxidative phosphorylation (OXPHOS), trigger adaptive metabolic rewiring, and interact with key oncogenic pathways, such as HIF-1α, BRAFV600E mutations, and TSHR signaling in thyroid cancer. We also highlight the emerging diagnostic and therapeutic potential of mtDNA in thyroid cancer and outline current challenges and future research directions. Gaining deeper insights into the mitochondria–metabolism axis may provide novel biomarkers and metabolic intervention strategies for precision medicine in thyroid oncology.


  • Open Access

    Molecular Mechanisms of Thyroid Hormone Signaling in Thyroid Cancer: Oncogenesis, Progression, and Therapeutic Implications

    by Changhao Zhou, Wei Liu, Jiaojiao Zheng, Qiao Wu, Zhilong Ai

    Thyroid cancer, as a highly hormone-dependent malignancy, is significantly regulated by thyroid hormones (T3/T4) and thyroid-stimulating hormone (TSH) signaling in its initiation and progression. This article comprehensively reviews the roles of thyroid hormones and their regulatory factor TSH in thyroid carcinogenesis and development, addressing related research from molecular mechanisms and clinical correlations to therapeutic strategies. It focuses on elucidating the impact of key mechanisms—such as elevated integrin αvβ3 expression and TRβ receptor mutations under hyperthyroid or hypothyroid conditions—on tumor progression. Furthermore, it evaluates the clinical utility and potential risks of TSH suppression therapy in patients stratified by risk, aiming to provide a theoretical basis for optimizing individualized treatment strategies.


  • Open Access

    Clinical performance of a machine learning-based model for detecting lymph node metastasis in papillary thyroid carcinoma: A multicenter study

    by Wei Liu, Jiaojiao Zheng, Liang Han, Weifeng Qu, Qiao Wu, Zhou Yuan, Gaolei Jia, Xiaolong Wang, Linxiong Ye, Jiaqi Zhang, et al.

    Papillary thyroid carcinoma (PTC) is a common endocrine malignancy with a generally favorable prognosis, but lymph node metastasis (LNM) complicates treatment and increases recurrence risk. Current preoperative methods like neck ultrasound often miss LNM, leading to unnecessary surgeries. This study developed a non-invasive, artificial intelligence (AI)-driven predictive model for LNM using gene expression data from 157 PTC patients and validated it with qRT-PCR across 807 participants from multiple centers. The model focused on three key genes – RPS4Y1, PKHD1L1, and CRABP1 – chosen for their predictive strength. A random forest algorithm achieved high accuracy, with an AUROC of 0.992 in training and 0.911–0.953 in external validation. RPS4Y1 emerged as a standout predictor, showing the strongest distinction between metastatic and non-metastatic cases. The study also identified immune-related pathways, such as TGF-β signaling and cancer-associated fibroblast activation, as critical in metastasis. This gene expression-based model offers a non-invasive, cost-effective solution for predicting LNM, providing valuable insights to guide surgical decisions and reduce unnecessary procedures, ultimately improving patient outcomes.